Project Grant R21CA284314
Award Date
9/22/23
Completion Date
8/31/25
Dollars Obligated
$246K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Argentina
Similar Awards
This $585,943 Cooperative Agreement awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop a low-cost, rapid, and easy-to-use point-of-care HPV DNA test to improve cervical cancer screening in Mozambique. The project will: 1) Adapt an extraction-free, multiplexed isothermal nucleic acid amplification assay to detect high-risk HPV types on an integrated nucleic acid amplification and lateral flow detection platform called NATFLOW; 2)...
This federal Cooperative Agreement award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) provides $706,365.00 to The Trustees of Columbia University in the City of New York to implement the evidence-based "screen, triage, and treat" (ISTAR) approach for cervical cancer screening among women living with HIV in La Romana, Dominican Republic. The project aims to sustain implementation of the ISTAR approach and generate new data to inform effective and...
This Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund a hybrid type III effectiveness-implementation trial to test best practices for deploying a "screen and treat" approach to cervical cancer screening utilizing self-collected HPV DNA testing within HIV care and treatment facilities in Mozambique. The 5-year, $643,363 project aims to improve access to affordable HPV testing and promote...
The National Cancer Institute (NCI) has awarded a $1,837,497 Cooperative Agreement under the Cancer Cause and Prevention Research (CFDA 93.393) program to New York University (NYU) for the KUPEWA project. The project aims to identify optimal implementation strategies for increasing clinician recommendation of HPV vaccination for girls and young women aged 9-24 living with HIV in Malawi. NYU is collaborating with the University of California, Los Angeles (UCLA) and the Malawi-based Partners In...
This federal Project Grant award of $368,070.00 from the National Cancer Institute (NCI), under the CFDA 93.393 Cancer Cause and Prevention Research program, supports research to identify and address barriers in the cervical cancer treatment cascade among women with HIV in South Africa. The primary awardee, Trustees of Boston University, will conduct qualitative interviews and a pilot randomized controlled trial to develop a multi-level retention care intervention tailored to the unique needs of...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) aims to develop and evaluate an intervention to improve cervical cancer screening and follow-up rates in three diverse, underserved populations: urban inner city Blacks/Haitians (Boston), Hispanic immigrants (Florida), and Hawaiian Natives/Pacific Islanders (Hawaii). The $753,446 award will be used to adapt a successful HPV vaccination intervention for cervical cancer screening,...
The National Cancer Institute (NCI) awarded a $629,068 Cooperative Agreement under the Cancer Cause and Prevention Research program (CFDA 93.393) to Albert Einstein College of Medicine for the project "Leveraging Project ECHO for Improved Cervical Cancer Screening in Ethiopia: An Implementation Study of Integrated HPV Self-Sampling in HIV Care Centers." The project aims to explore and address implementation challenges to cervical cancer screening in Ethiopia by integrating...
The National Cancer Institute (NCI) awarded a $300,374 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The University of South Dakota (USD) to develop and test a mobile web app intervention to promote cervical cancer screening among indigenous women. The 4-year project aims to increase cervical cancer screening rates among the Yankton Sioux Tribe (YST) in South Dakota, who experience disproportionately high cervical cancer morbidity and mortality. USD will...
The National Cancer Institute (NCI) awarded a $1,245,116 Cooperative Agreement under the Cancer Cause and Prevention Research (CFDA 93.393) program to Emory University to enhance cervical cancer screening and treatment for women living with HIV in Kenya. The project, titled "ENHANCING CERVICAL CANCER SCREENING AND TREATMENT IN WOMEN LIVING WITH HIV IN KENYA (ENHANCE LINKAGE)", aims to adapt and test evidence-based strategies, such as HPV self-testing, care navigators, and a mobile...
The National Cancer Institute (NCI) awarded a $191,700 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Northwestern University. The 5-year grant, which began on January 15, 2025, will support a pilot trial to assess the feasibility, acceptability, and effects of four digital intervention components (expert video, self-persuasion, narrative storytelling, and motivational interviewing) aimed at increasing HPV vaccination rates among the U.S. Vietnamese population. The...